January 2026: Biotech & Pharma NEWS Roundup
PETRI DISH PERSPECTIVES
Chapters
0:32
The China Connection: AbbVie Bets $1B on Zelgen’s Next-Gen Lung Cancer Fighter
1:09
Vanda Ends the 40-Year Wait: FDA Approves First New Motion Sickness Drug
1:37
Oxford’s Edge: Amgen Snags Dark Blue in $840M Leukemia Play
2:13
AI for Immunity: Sanofi and Earendil’s $2.5B Strategic Storm
2:46
The Generative Giant: Insilico Caps the Year with a Record $293
3:19
The $5.6 Billion Bispecific Battle: AbbVie Enters the PD-1xVEGF Fray
3:50
Divesting for Growth: Pfizer Exits ViiV Stake in $1.9B Strategic Shift
4:28
Closing the Allergy Gap: GSK Swallows RAPT Therapeutics for $2.2B
5:01
Obesity’s Global Reach: AstraZeneca’s Record $18.5B Alliance in China
5:40
Radiopharma’s New Star: Aktis Hits the Nasdaq with Lilly’s $100M Fuel
6:33
The Obesity Obsession: Lilly and Nimbus Ink $1.3B Sequel for Oral Weight-Loss
7:04
Lilly’s NLRP3 Lockdown: A $1.2B Buyout for Ventyx’s Inflammation Pipeline
7:39
Mapping the Cure: Lilly Puts $950M Behind InduPro’s Protein AI
8:12
Agentic AI: Lilly Enlists Chai Discovery to Build its Private Bio-Brain
8:44
The $1 Billion Brain Trust: NVIDIA and Lilly Launch AI ‘Super-Lab’
9:16
Rewriting the Code of Silence: Lilly’s $1.1B Bet on Gene-Edited Hearing
9:48
Retraining the Immune System: Lilly’s $1.9B Leap into ‘Tolerizing’ Tech
PETRI DISH PERSPECTIVES
January 2026: Biotech & Pharma NEWS Roundup
Feb 01, 2026
Manead Khin
Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026!
This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechNews #PharmaNews
© 2026 The Perspective Bureau LLC. All rights reserved.
